BigDNA Ltd will be re-branded as Iceni Pharmaceuticals during May 2016. Iceni Pharma is a drug development company aiming to take its lead product Cilcane (cilengitide) into clinical trials during 2016/17, initially for the blood cancer multiple myeloma. Iceni specializes in re-positioning and reformulating existing drugs for new disease indications. In contrast to the typical pharma model, this targeted strategy is designed to reduce the risk, the cost and the development time for effective new treatments and therefore maximize the chance of clinical success- for the benefit of patients, development partners and investors!